Interstitial Lung Disease Research Unit Biobank

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-08-09

Study Completion Date

2032-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

ILD-SARDs Registry and Biorepository

NCT05007340

Interstitial Lung Disease Systemic Autoimmune Disease Rheumatic Diseases +6 more

RECRUITING

Specialized Center of Research in Occupational and Immunologic Lung Disease

NCT00005280

Lung Diseases, Obstructive Asbestosis Silicosis +2 more

COMPLETED

Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)

NCT03478826

Interstitial Lung Disease

RECRUITING

Pulmonary Care and Research Collaborative Patient Registry

NCT05445817

Interstitial Lung Disease

UNKNOWN

Pulmonary Hypertension Biorepository and Registry

NCT04808596

Pulmonary Hypertension Pulmonary Arterial Hypertension Pulmonary Hypertension Due to Left Heart Disease +6 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The University of Kansas ILD and Rare Lung Disease clinic sees hundreds of new patients per year. The investigators would like to leverage this resource to develop an Interstitial Lung Disease Research Unit (ILDRU) repository and database to help develop new methods for early diagnosis, uncover underlying genetic and environmental risk factors, as well as potential treatment targets in the broad range of interstitial lung diseases and rare lung diseases (RLD).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Interstitial Lung Disease Sarcoidosis Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Hypersensitivity Pneumonitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The participant is a patient at TUKHS or has agreed to participate in a study approved by the KUMC Human Research Protection Program (HRPP)
2. The participant is being followed for the presence of autoimmune disease, ILD or other rare lung diseases at TUKHS.
3. The participant is ≥ 18 years of age.
4. The participant has signed an approved consent for this study (living patients only)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No